Oral treatment for moderate-to-severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests an oral medication (TLL-018) for people with moderate-to-severe atopic dermatitis (eczema) that hasn't been helped enough by topical treatments. The goal is to see if it can reduce symptoms like itching and skin inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had atopic dermatitis (also called eczema) for at least 1 year.
- Your eczema is moderate to severe, meaning it covers a large area of your body and causes significant itching.
- You have tried topical treatments (like creams or ointments) in the past 6 months and they didn't work well enough or you couldn't use them.
- You are willing to use moisturizers (emollients) twice a day during the study.
- You have not had serious infections (like shingles) recently, and you don't have other conditions like cancer, liver or kidney problems, or uncontrolled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental tablet (LT-002-158) for adults with moderate-to-severe eczema that hasn't improved enough with standard creams. The goal is to see if the tablet is safe and helps control symptoms.
This study tests an investigational drug (SIM0278) given as an injection to see if it helps reduce eczema symptoms. It is for people with moderate to severe atopic dermatitis who have not used certain other treatments recently.
This trial tests an oral pill called LW402 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug is safe and effective at reducing skin symptoms.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
This trial tests an oral medication (capsule) for moderate to severe atopic dermatitis (eczema) that has not responded well to other treatments. The goal is to see if it can reduce symptoms like itching and skin inflammation.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.